Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
beclometasone dipropionate + glycopyrronium bromide
- Development stage
- Unknown
- Lead developer
- Chiesi
- Modality
- Small Molecules
- Administration
- Inhalation
01
Overview
CHF 5259 + Qvar is an investigational combination therapy developed by Chiesi Farmaceutici for the treatment of uncontrolled asthma. It consists of CHF 5259, an extra-fine pressurized metered dose inhaler (pMDI) formulation of glycopyrronium bromide (a long-acting muscarinic antagonist or LAMA), administered as an add-on to QVAR (beclometasone dipropionate), an inhaled corticosteroid (ICS). Glycopyrronium bromide acts as a bronchodilator by antagonizing M3 muscarinic receptors in bronchial smooth muscle, while beclometasone dipropionate provides anti-inflammatory effects. This combination was evaluated in the Phase IIb ELITRA trial (NCT02296411) to assess its efficacy and safety in adult patients whose asthma remains uncontrolled on low-to-medium dose inhaled corticosteroids.
- Brand names
- Qvar
- Other names
- CHF 5259 + Qvarglycopyrrolate bromide + beclometasone dipropionateglycopyrronium bromide + beclometasone dipropionate
02
Targets
M1 (Muscarinic acetylcholine receptor M1)CHRM3 (M3)GR (Glucocorticoid receptor)CHRM2 (M2)MR (Mineralocorticoid receptor)
Beyond the preview
Go deeper on beclometasone dipropionate + glycopyrronium bromide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on beclometasone dipropionate + glycopyrronium bromide.